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Summary
The work described in this thesis deals with the pharmacokinetic properties (absorption,
distribution, metabolism and excretion) of several inhibitors of glycosidases.
Glycosidases are hydrolytic enzymes, including e.g. glucosidases and mannosidases, that are
involved in many physiological processes, such as glycoprotein synthesis. The glycosidase
inhibitors tudied are a mannosidase- and two glucosidase inhibitors derived from 1-deoxy-
nojirimycin (dNM), a polyhydroxylated indolizidine alkaloid that resembles glucose in its
pyranose conformation. They are secondary or tertiary amines, that are partly present in
the body as protonized cationic molecules.
In Chapter I an introduction is given on the function of glycoproteins and glycosida-
ses under physiological and pathological conditions. The role of glycosidase inhibitors as
potential drugs in the treatment of AIDS, cancer and metabolic disorders such as diabetes
is discussed and an overview is given of what is known up to now regarding pharmacology
and toxicologry of these group of compounds.
In Chapter 2 the pharmacokinetic properties of two derivatives of dNM are described
based on studies in rats after intravenous administration. The mannosidase I inhibitor 1-
deoxymannojirimycin (dMM) and the a-glucosidase inhibitor N-methyl-1-deorynojirimycin
(MedNM) exhibited minimal binding to rat plasma proteins and showed a rapid biphasic
plasma disappearance with an init ial t% of 3.0 and 4.5 min, respectively, and a terminal t%
of 5l and 32min, respectively. Forboth compounds renal excretion is the major route of
elimination. After 120 min, 52o/o of the dose of dMM and 80o/o of the dose of MedNM was
recovered unchanged from the urine, whereas only 4.9 and0.2o/o, respectively, of the dose
was excreted in bile. Urinary clearance of dMM was similar to the glomerular filtration
rate. In contrast, urinary clearance of MedNM was two to three times higher than the
glomerular f i l tration rate, indicating active tubular secretion. Ligation of the renal vessels
decreased the total-body clearance of dMM and MedNM 18- and 24-f<'id, respectively.
Neither alkalinization of the urine, by infusion of bicarbonate solutions, nor forced diuresis
altered the renal excretion rate of these compounds, implying the absence of tubular reab-
sorption. AÍ 120 min, the amounts of dMM in liver and kidney were 2.1 and l.7Vo of. the
dose, respectively, while small intestine, stomach, and heart contained only 0.9, 0.6 and
0.1Vo. Less than 7o/o of the dose of MedNM was tbund in the collected organs 2 hours
after injection. At the sitme time, the kidney/plasma concentration ratio of MedNM was
10-fold higher than in other tissues, whereas for dMM it was only 2 to 3-fold higher in
kidney, indicating a more persistent general t issue retention of dMM.
In Chapter 3 the hepatic disposition of the same two glycosidase inhibitors (doses 4
and 40 pmol) was studied in isolated perÍ'used rat livers and after subcellular fractionation
of rat l iver. dMM ancl MedNM exhibited minimal binding to bovine serum albumin present
in medium and reached live r concentrations that approximately equaled their medium con-
centrations, afïer 30 min (MedNM) or 90 min (dMM). Within two hours 05% of the dose
of MedNM anJ 2.9o/o of dMM were excreted in bile. No metabolites were found for
MedNM, whereas minor (bio)degradation was inferred for dMM. After subcellular fractio-
nation, dMM and MedNM were predominantly found in the cytosolic fraction. Compared
to the other particulate tiactions, MedNM was enriched in the microsomal fraction and
6both compounds were slightly enriched in the lysosomal fraction. MedNM at doses of 4,
40 and 720 p"mol dose-dependently inhibited glycogenolysis. Therefore it is concluded that
MedNM and dMM will inhibit l iver (lysosomal) enzymes when sufficient plasma levels are
reached.
In Chapter 4 a side-trip is made to membrane transport of some permanently
charged organic cations (quaternary amines), to study the potential transport mechanisms
of cationic forms of (model) drugs that can be taken up by l iver and excreted into bile but
also may accumulate in acidif ied intracellular organelles uch as lysosomes and endosomes.
These studies were undertaken to assess directly the uptake and accumulation of three
types of model organic cationic amines by endocyticvesicles and the role of vesicle acidif i-
cation in this process. Uptake of d-tubocurarine (TC; possessing two quaternary amine
functions), vecuronium (possessing a tertiary and a quaternary amine group) and tributyl-
methylammonium (TBuMA; possessing one quaternary amine group) by purif ied rat l iver
multivesicular bodies (MVB) (pre-lysosomal endocytic vesicles) was dependent upon
MgATP, time and drug concentration. After 60 minutes, 48 to 81o/o f MVB cation content
was dependent upon vesicle acidit lcation (due to an electrogenic proton pump) but not
upon an interior positive vesicle membrane potential. Nineteen ïo 52o/o of MVB cation
content appeared due to binding to MVB membranes or to internal l ipoproteins. Vesicle-
to-medium ATP-dependent apparent concentration ratios tbr these three cations were 3.3
to 51. MVB uptake of some of these cations resembled uptake of methylamine, a tertiary
amine known to distribute across organellar membranes according to pH gradients. For
TBuMA proton antiport seems to occur. By contrast, MVB uptake of the l ipophil ic quater-
nary amine methyldeptropine was not dependent upon MgATP or on development of
MVB pH ur membrane potential gradients. In further studies, TC, vecuronium and
TBuMA were shown to be rapidly taken up by the isolated perfused rat l iver and excreted
in bile. Exposure to 250 i.cM primaquin (which partially alkalinized acidic endosomes and
lysosomes) reduced accumulation of [3H]vecuronium in a lysosomal fraction hy 230/0,
decreased perfusate disappearance of TC and TBuMA, but not of vecuronium, ancl
decreased bil iary appearance of all three cations. These studies suggest that acidif ied intra-
cellular organelles ecluester certain organic cationic drugs, possibly vio a drug/ proton anti-
porter, and/or diffusion tollowed by intravesicular protonation and trapping of tertiary
amines. However, attempts of partial displacement of these drugs, accomplished through
partial vesicle alkalinization by primaquin, had only moderate et'fbcts on bil iary excretion
of TC, vecuronium and TBuMA. This perhaps retlects the small functional size of the dis-
placeable i lrganellar drug compartment and/or simultaneous competit ion between prima-
quin and the organic cations tbr membrane transport at the bile canalicular level.
In Chapter 5 the pharmacokinetic behavi<lr clf a new glucosidase inhibitclr, the anti-
viral compcrund /V-benzyl-1-deoxynojirimycin (B dNM), is described in rats irt vivo and in
isolated perfused rat l ivers. In addition, the subcellular distribution in rat l iver was investi-
gated. BndNM is a more l ipophil ic derivative of the glucosidase inhibitor N-methyl-l-
deoxynojirimycin (MedNM). This was retlected in the rr-octanol/Krebs partit ion coeffici-
ents, being 0.28 and 0.004, respectively. Derivtrt ization with the phenyl moiety caused an
increase in both elimination half-l i fe (frorn 32 min for MedNM to 69 min tirr BndNM) and
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steady-state distribution volume (164 ml for MedNM and 322 ml for BndNM) itt vivo.The
fraction of the dose excreted in urine after 2 hours was 66Vo (compared to 80Vo for
MedNM), the fraction excreted in bile after 2 hours was considerably higher, both in vlvo
(l.SVo of BndNM compared to 0.2Vo for MedNM) and in perfused livers (5% ïor BndNM
compared to 0.5% for MedNM). Clearance decreased from 6.3 (MedNM) to 4.0 ml/min
(BndNM). In unanesthetized rats, bioavailability of BndNM was found to be I00Vo after
oral dosing. Fractionation of liver homogenates showed that BndNM was mainly present
in the cytosolic fraction, with no specific concentration in any of the subcellular fractions
isolated. We conclude that addition of the lipophilic phenyl group to MedNM optimized
the pharmacokinetic properties of the glucosidase inhibitor.
In Chapter 6 the pharmacokinetics, biodistribution and excretion of BndNM is
described based on studies in mice, after intravenous, subcutaneous and oral administration
of a single radiolabeled dose. No metabolites were detected in plasma, urine or faeces-
extracts. BndNM also showed a bi-exponential plasma decay in mice, with half-lives of 9
and 62 min. The mean bioavailability was 89Vo after subcutaneous dosing, and 82Vo aïter
oral dosing to fed mice. Decay curves of BndNM in blood plasma and total blood coinci-
ded exactly for all routes of administration, indicating equal concentrations in plasma and
blood cells. Tissue concentrations of BndNM were higher than plasma concentrations at
all t ime points (0.5-24 hours), in all collected tissues (kidney, l iver, large and small intes-
tines and stomach), but especially in kidney, where tissue/plasma concentration ratios of
10-15 were reached. Small amounts of BndNM were recovered from collected gallbladders,
not exceeding 0.1o/o ï dose. The recovery of BndNM in urine and faeces was determined
and compared to MedNM (values between square brackets), a hydrophilic dNM derivative
that was also not metabolized. After 24 hours, small fractions of the dose were recovered
from faeces: 1.2o/o [0.8o/o] atier subcutaneous dosing,4.2Vo [7.6Vo] after oral dosing and
4.9% l4.8Vol after intravenous dosing. Much larger fractions were recovered from the
urine, being largest after subcutaneous administration (78o/o l91Vol), followed by oral (680/o
[70o/ol) and intravenous (54Va l52Vo]) dosing 6 hours after administration. After 24 hours
the percentages were 9l [98], 89 [78] and 75 [701o/o, respectively. The substantially lower
recovery of both compounds after intravenous dosing cannot easily be explained, and was
not observed in similar experiments in rats, where, 6'hours after intravenous dosing of
BndNM, in urine 73%o oï dose was recovered compared to 64Vo after oral dosing. After
24 hours these values were 85 and 88o/o, respectively.
In Chapter 7 the plasma disappearance and corresponding pharmacokinetic para-
meters of BndNM and MedNM are compared employing the data of the studies in rats
and mice (as described in Chapters 5 and 6). In mice, the plasma disappearance curves of
both compounds almost coinsided aÍïer intravenous (i.v.), subcutaneous and oral admini-
stration. In (anesthetized) rats, the compounds displayed comparable init ial half-l ives but
clearly different elimination halt'-lives atter i.v. administration, due to faster (renal) clear-
ance of MedNM together with a smaller volume of distribution for this compound. In rats,
for BndNM a difference in pharmacokinetic behavior was seen when given to anesthetized
compared to unanesthetized animals. In the latter case, BndNM disappeared much faster
from plasma, due to a higher clearance, while the terminal halflives were equal in both
8situations. When BndNM was administered i.v. t<l mice, both init ial and terminal halt-l i fe
were comparable to the studies in rats, but clearance in mice was much taster leading to
lower terminal plasma concentrations at equal dosing on the basis of body weight. Because
BndNM was studied extensively in two species, an zrttempt was made to extrapolate kinetic
parameters to humans. Clearance and glomerular f i l tration rate (GFR) correlated well with
body weight in a multiple l inear regression analysis, leading to a predicted value for clear-
ance in humans of 500 mlimin, which is approximately 4 times the GF-R. The terminal half-
l ive and volume of distribution in humans could not be predicted, because the data díd not
obey pharmacokinetic laws sutïciently.
In Chapter 8 the results of the studies presented in this thesis and implications for
further research are discussed. Further development ofglycosidase inhibitors should focuss
on issues as longer duration of action and cell-specific delivery of these compounds to
reduce side-etfècts that can be anticipated atïer long-term treatment.
These studies were pertirrmed at the Department of Pharmacology and Therapeutics
of the University Center tbr Pharmacy, University of Groningen, The Netherlands, which
participates in the Groningen Institute lbr Drug Studies (GIDS). Parts of the project were
performed in collaberation with Organon International BV, Oss, The Netherlands, the
Netherlands Cancer Institute, Amsterdam, The Netherlands, and the Liver Center of the
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